EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds/defects and epitheliopathies, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body, as well as Eyegate II drug delivery system. The company has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-788-8869
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$410,000.00
Profitability
Miscellaneous
Employees17
OptionableNot Optionable
Eyegate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions
What is Eyegate Pharmaceuticals' stock symbol?
Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."
How were Eyegate Pharmaceuticals' earnings last quarter?
Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) announced its quarterly earnings data on Tuesday, November, 13th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.01. The specialty pharmaceutical company had revenue of $0.32 million for the quarter, compared to analysts' expectations of $0.19 million. View Eyegate Pharmaceuticals' Earnings History.
When is Eyegate Pharmaceuticals' next earnings date?
What price target have analysts set for EYEG?
1 analysts have issued 1-year price objectives for Eyegate Pharmaceuticals' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Eyegate Pharmaceuticals' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,081.1% from the stock's current price. View Analyst Price Targets for Eyegate Pharmaceuticals.
What is the consensus analysts' recommendation for Eyegate Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyegate Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyegate Pharmaceuticals.
Has Eyegate Pharmaceuticals been receiving favorable news coverage?
Media headlines about EYEG stock have been trending positive recently, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eyegate Pharmaceuticals earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.
Are investors shorting Eyegate Pharmaceuticals?
Eyegate Pharmaceuticals saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 498,717 shares, a decrease of 41.2% from the December 14th total of 848,269 shares. Based on an average daily volume of 268,160 shares, the days-to-cover ratio is presently 1.9 days. Currently, 1.5% of the shares of the stock are short sold. View Eyegate Pharmaceuticals' Current Options Chain.
Who are some of Eyegate Pharmaceuticals' key competitors?
Some companies that are related to Eyegate Pharmaceuticals include Ovid Therapeutics (OVID), Acasti Pharma (ACST), Mersana Therapeutics (MRSN), Pharmaxis (PXSLY), Provention Bio (PRVB), Iterum Therapeutics (ITRM), VERONA PHARMA P/S (VRNA), Humanigen (HGEN), Alpine Immune Sciences (ALPN), Medicure (MCUJF), Entasis Therapeutics (ETTX), Aridis Pharmaceuticals (ARDS), Elite Pharmaceuticals (ELTP), CTI BioPharma (CTIC) and Infinity Pharmaceuticals (INFI).
Who are Eyegate Pharmaceuticals' key executives?
Eyegate Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen From, Pres, CEO & Director (Age 56)
- Dr. Barbara M. Wirostko, Chief Medical Officer (Age 53)
- Mr. Michael P. Manzo, VP of Engineering (Age 60)
- Ms. Sarah Romano, Chief Financial Officer
- Mr. Mike Garanzini, Chief Commercial Officer
When did Eyegate Pharmaceuticals IPO?
(EYEG) raised $5 million in an initial public offering on Friday, February 13th 2015. The company issued 800,000 shares at a price of $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.
Who are Eyegate Pharmaceuticals' major shareholders?
Eyegate Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.16%). Company insiders that own Eyegate Pharmaceuticals stock include Armistice Capital Master Fund, Morton Goldberg, Sarah Romano and Stephen From. View Institutional Ownership Trends for Eyegate Pharmaceuticals.
Which institutional investors are buying Eyegate Pharmaceuticals stock?
EYEG stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Eyegate Pharmaceuticals stock in the last two years include Armistice Capital Master Fund, Sarah Romano and Stephen From. View Insider Buying and Selling for Eyegate Pharmaceuticals.
How do I buy shares of Eyegate Pharmaceuticals?
Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eyegate Pharmaceuticals' stock price today?
One share of EYEG stock can currently be purchased for approximately $0.5080.
How big of a company is Eyegate Pharmaceuticals?
Eyegate Pharmaceuticals has a market capitalization of $22.07 million and generates $410,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,210,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Eyegate Pharmaceuticals employs 17 workers across the globe.
What is Eyegate Pharmaceuticals' official website?
How can I contact Eyegate Pharmaceuticals?
Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.
MarketBeat Community Rating for Eyegate Pharmaceuticals (NASDAQ EYEG)
MarketBeat's community ratings are surveys of what our community members think about Eyegate Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYEG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEG will underperform the S&P 500 over the long term. You may vote once every thirty days.
